EMA100 support holding still since 4/10 @.0569 although
EMA100 support holding still since 4/10 @.0569 although MACD Negative Convergence shows Bears are still in control. If EMA100 support breaks then look for good buying opportunity just over the SMA100 support level @.0477 unless significant news (licensing, etc) occurs.
This is not likely due to
(a) large quantity of formerly restricted stock entering the market
(b) construction completion time constraints and
(c) because much needed DINRA/SEC impact in the MJ sector overall.
Look for entry points at MACD crossover in combination with typically used confirmations.
IMO I believe this market price movement is more a correction sector wide (MJ). Bigger money is likely to stay out of the market until several key things happen including
(1) FINRA/SEC cleanup,
(2) formerly RS entering the market are absorbed enough to reduce significant dilution as it relates to market entry.
The market will eventually consolidate and this sector will then grow rapidly. For longs (like myself), I continue buying on dips and target SMA/EMA using GTC Limit orders. Even with licensing there will be lots of movement in pricing as market share/revenues, etc., replace more intrinsic valuations.
THIS MARKET IS NOT GOING AWAY!!!! It will experience many bumps along the way as it grows and pps will fluctuate widely as a result. Just getting a license does not mean ownership of marketshare, not to mention the impact of yet to be developed and much needed regulations industry wide.
Why is this sector here to stay? TAX REVENUES and INDUSTRY CONTROL to protect those revenues and the market. Tax revenues are badly needed to support social programs in both the USA and Canada. The model for regulations and controls being implemented by Canada, or one similar to it, will eventually be implemented in the USA and will come under the medicinal and hemp (product) banner.
Note to Mods.
A previous post I did based on charting was deleted. Probably because I made a comment on SS. Please note that SS is an integral component of market valuation and has potential for significant impact on pps depending on when shares are designed to enter the market and for what purpose. I believe this board generally tries to be objective and provides useful information to its readers. I welcome anyone on this board to check price action against charting and provide their input, this only helps investors such as you and me to hopefully preserve and grow our capital for future use.
Your comments are appreciated.
Creative Edge Nutrition Inc. (FITX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...
Continue Reading
Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...
Continue Reading
Riding the Waves of Real Estate Pricing Homeowners dipping their toes into the real estate market know that setting the right price ain't a walk in the park. Luckily, Matt Nuzie, Shelton's real estate pro, has peeled back the layers on comparative market analyses (CMA) in a HelloNation piece. This isn't just about tossing a number out there—it's about understanding the...
Continue Reading
Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...
Continue Reading
Gildan's Legal Storm: Fraud Allegations When news hits about a big player like Gildan Activewear (NYSE: GIL) facing a class-action lawsuit, it's like a thunderstorm for investors who traded their stocks between February 19, 2025, and June 15, 2026. This lawsuit alleges what we some might call classic financial engineering—channel stuffing to be precise—that’s got...
Continue Reading
Small Component, Big Impact: The Anode Rod Picture this: You’ve got a trusty water heater keeping your showers steamy, but lurking inside is a villain called rust. Enter the unsung hero—the anode rod. It might not be glamorous, but this little piece of metal works overtime to save your tank from a watery grave. Tim Fessler and Dave Super, seasoned plumbing hotshots...
Continue Reading
Building Bridges Across Waters These aren't the afternoons of trading stocks, folks—this one dives into the depths of the ocean and the tumultuous waters between China and Malaysia. October 30 saw the China-Malaysia Youth Ocean Dialogue take place at the China Media Group Sanya Studio, bringing together some sharp minds from both nations, tackling something that goes...
Continue Reading
What's the Deal With Those Ancient Quotes? There's nothing like a quote from the Warring States Period to set the stage for good ol' fashioned governance chatter. Lu Buwei's words about rulers and compass points is historic, sure, but it speaks to the core need for standards in today's China. This isn't just some fortune cookie wisdom; it's a clarion call for order and...
Continue Reading
When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...
Continue Reading
Rethinking AI with Sovereignty in Mind A bouquet of tech buzzwords lands on every investor's doorstep with the unveiling of Context Labs' latest contraption. We’re talking about the AI Distillery™, which promises enterprises a way to run sovereign AI systems by keeping data in-house. Now, if you’re nodding along to the buzz, let's cut through the clutter....
Continue Reading
Top 5 Most Recently Viewed Articles
Logan Ridge Finance Corporation Announces Q1 2025 Earnings Release Logan Ridge Finance Corporation (NASDAQ: LRFC) has scheduled to share its financial results for the first quarter soon, wrapping up on March 31, 2025. The eagerly awaited earnings release will occur on a Thursday, with a conference call slated for a Friday morning where investors and stakeholders can gain...
Continue Reading
Maxus Mining Uncovering High-Grade Mineralization at Alturas East Maxus Mining Inc. (CSE: MAXM | FRA: R7V) recently published highlights from its 2025 exploration program at the Alturas Project, which is situated in British Columbia's Slocan Mining Division. The Alturas East Block, a key focus area, spans over 1,094 hectares known for containing rich mineral resources and...
Continue Reading
Growing Interest in Lightweight Pre-Insulated Pipes The global market for pre-insulated pipes was valued at USD 6.1 billion in 2023 and is expected to grow significantly, with projections indicating it could reach USD 11.2 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of 5.7%, with an anticipated year-on-year increase of 6.3% in the near...
Continue Reading
Market Surge for Korro Bio and Its Implications In a remarkable display of market confidence, Korro Bio's stock has soared to a 52-week high, reaching an impressive price level of $98.0 USD. This significant milestone reflects a period of notable growth for the company, having achieved an astonishing 433.96% increase over the past year. Investors have enthusiastically...
Continue Reading
Merck's New Challenge in Colorectal Cancer Treatment In a key development in medical science, Merck has revealed that its newest therapy designed for a specific type of colorectal cancer fell short of its main goals during a late-stage trial. This news is significant not just for patients but also for healthcare professionals, as the quest for effective treatments...
Continue Reading